Compugen Q1 Revenue $2.2M, Cash Sufficient Until 2029
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Reports Q1 revenue $2.2M vs. $2.3M last year. Compugen expects that its cash and cash-related balances will be sufficient to fund its operating plans into 2029. The company has no debt. "Q1 2026 reflects continued execution across all of our programs in line with our strategic priorities," said CEO Eran Ophir. "With enrollment progressing across all COM701 MAIA-ovarian trial sites, we remain on track for having the median progression-free survival at the interim analysis by Q1 2027, a key potential inflection point for COM701 as a maintenance therapy in a patient population with significant unmet medical need and no current standard of care. Our partner AstraZeneca continues to broadly advance rilvegostomig. In addition, we continue to advance the Gilead-partnered GS-0321 Phase 1 trial. Our solid financial position with cash runway expected into 2029, based on our current plans, enables us to advance our differentiated immuno-oncology pipeline and leverage our AI/ML powered computational discovery platform Unigen, to discover novel ways to activate the immune system against cancer. I remain encouraged by the progress of our fully owned programs, strengthened by validating partnerships with AstraZeneca and Gilead, which together offer approximately $1B in potential milestones plus royalties."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGEN
Wall Street analysts forecast CGEN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.220
Low
4.00
Averages
4.00
High
4.00
Current: 2.220
Low
4.00
Averages
4.00
High
4.00
About CGEN
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compugen Reports Q1 2026 Financial Results and Corporate Update
- Strong Financial Position: As of March 31, 2026, Compugen reported approximately $134.9 million in cash and cash equivalents, indicating a solid financial foundation that supports operational plans into 2029, allowing continued advancement of its immuno-oncology pipeline.
- Slight Revenue Decline: The company generated approximately $2.2 million in revenue for Q1 2026, a minor decrease from $2.3 million in Q1 2025, reflecting fluctuations in revenue sources that necessitate attention to future growth strategies.
- Increased R&D Expenses: R&D expenses for Q1 2026 were approximately $6.9 million, up from $5.8 million in the same period of 2025, primarily due to rising clinical costs associated with the MAIA-ovarian trial, demonstrating the company's commitment to clinical development.
- Stable Net Loss: Compugen reported a net loss of approximately $7.7 million for Q1 2026, with a loss per share of $0.08, consistent with the previous year's results, indicating effective loss control while continuing to invest in R&D and operations.
See More
Compugen Q1 Earnings: Revenue Beats Expectations
- Revenue Performance: Compugen reported Q1 revenue of $2.18 million, a 4.4% year-over-year decline, yet it exceeded expectations by $0.92 million, indicating effective revenue management despite a challenging market environment.
- Earnings Per Share: The GAAP EPS of -$0.08 missed expectations by $0.01, reflecting pressure on profitability that could impact investor confidence and future stock performance.
- Cash Position: As of March 31, 2026, Compugen had approximately $134.9 million in cash and cash equivalents, which is expected to fund its operating plans into 2029, demonstrating financial stability and operational sustainability.
- Debt-Free Advantage: Compugen currently holds no debt, providing financial flexibility for future investments and expansions, thereby enhancing its competitive position within the industry.
See More
Compugen Scheduled to Announce Q1 Earnings on May 18
- Earnings Announcement: Compugen (CGEN) is set to release its Q1 2023 earnings on May 18 after market close, with a consensus EPS estimate of -$0.08, indicating ongoing challenges in profitability.
- Revenue Decline Expected: Analysts project revenue to be $1.26 million, reflecting a significant 45.2% year-over-year decline, highlighting competitive pressures and weak product sales.
- Historical Performance Review: Over the past two years, Compugen has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, indicating a degree of stability in its financial performance.
- Funding and Product Progress: Compugen has secured non-dilutive funding to support the development of Rilvegostomig and advance GS-0321, demonstrating proactive measures in research and funding management.
See More
Compugen to Present at 2026 Stifel Virtual Oncology Forum
- Forum Presentation Scheduled: Compugen Ltd. will present at the 2026 Stifel Virtual Oncology Forum on May 19, 2026, from 10:00 to 10:25 AM ET, showcasing its latest advancements in cancer immunotherapy, which is expected to attract attention from investors and industry experts.
- Innovative Platform Overview: Utilizing its AI/ML-powered Unigen™ computational discovery platform, Compugen is focused on identifying novel drug targets and developing cancer immunotherapies, highlighting its four clinical-stage programs, including COM701 and COM902, which possess significant market potential.
- Clinical Trial Progress: Compugen is currently conducting the MAIA-ovarian trial, evaluating COM701 as a single agent in maintenance therapy for relapsed platinum-sensitive ovarian cancer, and if successful, it will provide new treatment options for patients, enhancing the company's influence in oncology.
- Collaborative Development Dynamics: Under an exclusive licensing agreement with AstraZeneca, rilvegostomig, a PD-1/TIGIT bispecific antibody, is undergoing multiple clinical trials, and positive results could further solidify Compugen's position in the cancer treatment market.
See More
Compugen to Release Q1 2026 Financial Results on May 18
- Earnings Release Schedule: Compugen will announce its Q1 2026 financial results on May 18 before U.S. markets open, with management hosting a conference call and webcast at 8:30 AM ET to provide updates on corporate performance and financial results.
- Clinical Trial Progress: The ongoing MAIA-ovarian trial evaluates COM701 as a single agent for maintenance therapy in relapsed platinum-sensitive ovarian cancer, reflecting the company's commitment to advancing cancer immunotherapy research.
- Collaborative Development Projects: Under an exclusive licensing agreement with AstraZeneca, Compugen's PD-1/TIGIT bispecific antibody rilvegostomig is undergoing multiple clinical trials, indicating a strategic partnership approach to developing new therapies with major pharmaceutical companies.
- Innovative Drug Pipeline: Compugen's immuno-oncology pipeline features four clinical-stage programs, including potential first-in-class and best-in-class antibodies, showcasing the company's leadership in utilizing AI/ML technologies for novel drug target discovery.
See More
Compugen to Present at 25th Annual Needham Virtual Healthcare Conference
- Conference Schedule: Compugen will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 8:45 to 9:25 AM ET, which is expected to enhance the company's visibility in the capital markets by attracting investor and industry expert attention.
- Technology Platform Overview: Compugen leverages its AI/ML-powered computational discovery platform, Unigen™, to identify novel drug targets and biological pathways for cancer immunotherapy, showcasing the company's innovative capabilities and technological advantages in cancer treatment.
- Clinical Progress Update: Compugen's COM902 anti-TIGIT antibody is currently in Phase 1 development, while rilvegostomig is in Phase 3 development under AstraZeneca, indicating the company's active progress in clinical trials and potential for collaboration.
- Diverse Pipeline Strategy: Compugen's early-stage immuno-oncology projects include potential first-in-class antibodies like COM701 and GS-0321, reflecting the company's strategic positioning and market prospects in developing new mechanisms to activate the immune system against cancer.
See More
Compugen Reports Q1 2026 Financial Results and Corporate Update
- Strong Financial Position: As of March 31, 2026, Compugen reported approximately $134.9 million in cash and cash equivalents, indicating a solid financial foundation that supports operational plans into 2029, allowing continued advancement of its immuno-oncology pipeline.
- Slight Revenue Decline: The company generated approximately $2.2 million in revenue for Q1 2026, a minor decrease from $2.3 million in Q1 2025, reflecting fluctuations in revenue sources that necessitate attention to future growth strategies.
- Increased R&D Expenses: R&D expenses for Q1 2026 were approximately $6.9 million, up from $5.8 million in the same period of 2025, primarily due to rising clinical costs associated with the MAIA-ovarian trial, demonstrating the company's commitment to clinical development.
- Stable Net Loss: Compugen reported a net loss of approximately $7.7 million for Q1 2026, with a loss per share of $0.08, consistent with the previous year's results, indicating effective loss control while continuing to invest in R&D and operations.
See More
Compugen Q1 Earnings: Revenue Beats Expectations
- Revenue Performance: Compugen reported Q1 revenue of $2.18 million, a 4.4% year-over-year decline, yet it exceeded expectations by $0.92 million, indicating effective revenue management despite a challenging market environment.
- Earnings Per Share: The GAAP EPS of -$0.08 missed expectations by $0.01, reflecting pressure on profitability that could impact investor confidence and future stock performance.
- Cash Position: As of March 31, 2026, Compugen had approximately $134.9 million in cash and cash equivalents, which is expected to fund its operating plans into 2029, demonstrating financial stability and operational sustainability.
- Debt-Free Advantage: Compugen currently holds no debt, providing financial flexibility for future investments and expansions, thereby enhancing its competitive position within the industry.
See More
Compugen Scheduled to Announce Q1 Earnings on May 18
- Earnings Announcement: Compugen (CGEN) is set to release its Q1 2023 earnings on May 18 after market close, with a consensus EPS estimate of -$0.08, indicating ongoing challenges in profitability.
- Revenue Decline Expected: Analysts project revenue to be $1.26 million, reflecting a significant 45.2% year-over-year decline, highlighting competitive pressures and weak product sales.
- Historical Performance Review: Over the past two years, Compugen has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, indicating a degree of stability in its financial performance.
- Funding and Product Progress: Compugen has secured non-dilutive funding to support the development of Rilvegostomig and advance GS-0321, demonstrating proactive measures in research and funding management.
See More
Compugen to Present at 2026 Stifel Virtual Oncology Forum
- Forum Presentation Scheduled: Compugen Ltd. will present at the 2026 Stifel Virtual Oncology Forum on May 19, 2026, from 10:00 to 10:25 AM ET, showcasing its latest advancements in cancer immunotherapy, which is expected to attract attention from investors and industry experts.
- Innovative Platform Overview: Utilizing its AI/ML-powered Unigen™ computational discovery platform, Compugen is focused on identifying novel drug targets and developing cancer immunotherapies, highlighting its four clinical-stage programs, including COM701 and COM902, which possess significant market potential.
- Clinical Trial Progress: Compugen is currently conducting the MAIA-ovarian trial, evaluating COM701 as a single agent in maintenance therapy for relapsed platinum-sensitive ovarian cancer, and if successful, it will provide new treatment options for patients, enhancing the company's influence in oncology.
- Collaborative Development Dynamics: Under an exclusive licensing agreement with AstraZeneca, rilvegostomig, a PD-1/TIGIT bispecific antibody, is undergoing multiple clinical trials, and positive results could further solidify Compugen's position in the cancer treatment market.
See More
Compugen to Release Q1 2026 Financial Results on May 18
- Earnings Release Schedule: Compugen will announce its Q1 2026 financial results on May 18 before U.S. markets open, with management hosting a conference call and webcast at 8:30 AM ET to provide updates on corporate performance and financial results.
- Clinical Trial Progress: The ongoing MAIA-ovarian trial evaluates COM701 as a single agent for maintenance therapy in relapsed platinum-sensitive ovarian cancer, reflecting the company's commitment to advancing cancer immunotherapy research.
- Collaborative Development Projects: Under an exclusive licensing agreement with AstraZeneca, Compugen's PD-1/TIGIT bispecific antibody rilvegostomig is undergoing multiple clinical trials, indicating a strategic partnership approach to developing new therapies with major pharmaceutical companies.
- Innovative Drug Pipeline: Compugen's immuno-oncology pipeline features four clinical-stage programs, including potential first-in-class and best-in-class antibodies, showcasing the company's leadership in utilizing AI/ML technologies for novel drug target discovery.
See More
Compugen to Present at 25th Annual Needham Virtual Healthcare Conference
- Conference Schedule: Compugen will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 8:45 to 9:25 AM ET, which is expected to enhance the company's visibility in the capital markets by attracting investor and industry expert attention.
- Technology Platform Overview: Compugen leverages its AI/ML-powered computational discovery platform, Unigen™, to identify novel drug targets and biological pathways for cancer immunotherapy, showcasing the company's innovative capabilities and technological advantages in cancer treatment.
- Clinical Progress Update: Compugen's COM902 anti-TIGIT antibody is currently in Phase 1 development, while rilvegostomig is in Phase 3 development under AstraZeneca, indicating the company's active progress in clinical trials and potential for collaboration.
- Diverse Pipeline Strategy: Compugen's early-stage immuno-oncology projects include potential first-in-class antibodies like COM701 and GS-0321, reflecting the company's strategic positioning and market prospects in developing new mechanisms to activate the immune system against cancer.
See More
